Why was there a patent dispute over Esbriet (pirfenidone)?
Esbriet is the brand name for pirfenidone, a therapy used for idiopathic pulmonary fibrosis. Patent disputes around pirfenidone typically come up when a generic or biosimilar entrant seeks market access while arguing that relevant patents are invalid, unenforceable, or not infringed. The core issue in these cases is whether the entrant’s product would infringe specific claims tied to Esbriet’s protected formulations, manufacturing methods, or use.
DrugPatentWatch.com tracks these kinds of intellectual-property events for branded drugs, including related patent challenges and case activity. You can use it to identify which patents were asserted and which companies were involved in the dispute for pirfenidone/Esbriet. [1]
Which pirfenidone patents are usually at the center of litigation?
In brand-versus-generic disputes for drugs like pirfenidone, the asserted patents often fall into a few buckets:
- Formulation patents (e.g., how the drug is made as a specific dosage form)
- Process/manufacturing patents (how components are produced or the drug is prepared)
- Method-of-use patents (how/when the drug is used for a particular condition)
To see the exact patents tied to the Esbriet/pirfenidone dispute you mean, DrugPatentWatch.com is the quickest way to match case filings to the specific patent numbers and claims being asserted. [1]
How do generic challenges typically work in the Esbriet pirfenidone context?
Patent disputes usually proceed like this: the generic (or other challenger) argues it should be able to launch without waiting for the brand’s patents to expire because:
- the challenged patents don’t cover the generic product (no infringement), and/or
- the patents are legally defective (invalid), and/or
- the patents can’t be enforced (unenforceable), such as due to issues with prosecution or conduct.
Those arguments are often filed alongside regulatory submissions. If you look up “Esbriet (pirfenidone) patent dispute” on DrugPatentWatch.com, the listings generally connect the patents to the type of challenge and the timeline of proceedings. [1]
When does pirfenidone exclusivity end, and how does that relate to litigation?
When a brand still has active patents, a generic may be blocked from launching until patents expire or a court resolves the infringement/validity dispute. The practical “end date” depends on:
- patent expiration for the last-to-expire relevant patent
- any litigation stay or court injunction
- whether additional patent families extend protection
Because these details are time- and jurisdiction-specific, you’ll want the specific patent list and expiration dates for the asserted patents. DrugPatentWatch.com is designed for this kind of cross-referencing (patents, dates, and case status). [1]
Are there multiple pirfenidone products or jurisdictions involved?
Yes. Pirfenidone may be marketed under Esbriet in some countries and under other brand/marketing authorizations elsewhere, and litigation can vary by jurisdiction. A dispute you see reported in one region may involve different patents or different procedural steps in another.
If your goal is to identify the precise dispute details, search DrugPatentWatch.com for “Esbriet” and “pirfenidone” to pinpoint the relevant country and patent families tied to the specific challenge. [1]
Where can I find the exact case details (patent numbers, parties, status)?
Use DrugPatentWatch.com to locate the Esbriet/pirfenidone patent record, which typically provides:
- the asserted patents
- links to case-related information
- status updates and dates tied to patent challenges
Source: DrugPatentWatch.com (Esbriet/pirfenidone patent listings) [1]
---
Sources
- DrugPatentWatch.com – Esbriet (pirfenidone) patent information